http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-079022-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C307-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D335-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D335-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D335-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D305-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D305-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D313-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D305-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 |
| filingDate | 2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-079022-A1 |
| titleOfInvention | DERIVATIVES OF CYCLIC CARBOXYL ACID SUBSTITUTED WITH ACILAMINE, ITS USE AS PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD |
| abstract | Claim 1: A compound of formula 1, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any proportion, or a pharmaceutically acceptable salt thereof, wherein ring A is a 3-membered monocyclic, bicyclic or spirocyclic ring. 12-member, comprising 0, 1 or 2 equal or different hetero ring members chosen from the series consisting of N, N (R0), O, S, S (O) and S (O) 2, and which is saturated or comprises 1 double bond, with the proviso that ring A is not a bicyclo [3.1.0] hexane or bicyclo [3.2.0] heptane ring having the groups N (R20) and C (O) -R50 in its position 3, and is not an octahydropentalene, octahydroindene or decahydroazulene ring that has the groups N (R20) and C (O) -R50 in its position 2, where ring A is optionally substituted at the carbon atoms of the ring with one or more equal or different substituents chosen from the series consisting of halogen, R1, R2, alkenyl C2-6, HO-, R1-O-, phenyl-C1-4-O- alkyl, R1-C (O) -O-, R1S (O) 2-O-, R1-S (O) m-, H2N-, R1-NH-, R1-N (R1) -, R1-C (O) -NH, R1-C (O) -N (R1) -, R1-S (O) 2-NH-, R1 -S (O) 2-N (R1) -, R1-C (O) -, HO-C (O) -, R1-OC (O) -, H2N-C (O) -, R1-NH-C (O) -, R1-N (R1) -C (O) -, H2N-S (O) 2-, R1-NH-S (O) 2-, R1-N (R1) -S (O) 2 -, F5S-, NC-, oxo and methylene; Y is selected from the series consisting of N (R10), S, O, C (R12) = C (R13), N = C (R14) and C (R15) = N; Z is selected from the series consisting of N and C (R16); R0 is selected from the series consisting of hydrogen and R1; R1 is selected from the series consisting of C1-6 alkyl, C3-7 cycloalkyl and C3-7 cycloalkyl-C1-4 alkyl; R2 is C1-4 alkyl which is substituted with one or more same or different substituents chosen from the series consisting of HO- and C1-4-O- alkyl; R10 is selected from the series consisting of hydrogen and R11; R11, R30, R33, R35, R54, R55, R57 and R58 are, independently of each other, a group R11, R30, R33, R35, R54, R55, R57 and R58, chosen from the series consisting of C1-6 alkyl , C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl and C3-7 cycloalkyl-C 1-4 alkyl alkyl which are all optionally substituted with one or more same or different R70 substituents; R12, R13, R14, R15 and R16 are chosen, independently from each other, from the series consisting of hydrogen, halogen, alkyl, HO-C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkyl (O) m, H2N-, C1-4-NH- alkyl, C1-4-N alkyl (C1-4 alkyl) -, C1-4-C alkyl (O) - and NC-, or R13 or R14, together with one of the groups R21 and R22 which is not the group of the formula (2), it forms a chain consisting of 3 to 5 chain members of which 0, 1 or 2 chain members are equal hetero or chain members different chosen from the series consisting of N (R17), O and S, but two hetero chain members may not be present in adjacent positions, and the other chain members are the same or different C (R18) (R18) groups; R17 and R25 are selected, independently from each other, from the series consisting of hydrogen and C1-4 alkyl; R18, independently of any other R18 group, is chosen from the series consisting of hydrogen, fluorine and C1-4 alkyl, or two of the R18 groups attached to the same carbon atom, together with the carbon atom that has them, forms a 3-membered to 6-membered cycloalkane ring that is optionally substituted with one or more same or different substituents chosen from the series consisting of fluorine and C 1-4 alkyl; R20 is selected from the series consisting of hydrogen and C1-4 alkyl; one of the groups R21 and R22 is a group of the formula (2) (R24-R23-) and the other of the groups R21 and R22 is chosen from the series consisting of hydrogen, halogen, R30, HO-, R30- O-, R30-C (O) -O-, R30-S (O) 2-O-, R30-S (O) m, H2N-, R30-NH-, R30-N (R30) -, R30- C (O) -NH-, R30-C (O) -N (R71) -, R30-S (O) 2-NH-, R30-S (O) 2-N (R71) -, R30-C ( O) -, HO-C (O) -, R30-OC (O) -, H2N-C (O) -, R30-NH-C (O) -, R30-N (R30) -C (O) - , H2N-S (O) 2-, R30-NH-S (O) 2-, R30-N (R30) -S (O) 2-, NC-, O2N- and Het1, or together with R13 or R14 form a string as specified in the definition of R13 and R14; R23 is a direct link or a chain consisting of 1 to 5 chain members of which 0, 1 or 2 chain members are equal or different hetero chain members chosen from the series consisting of N (R25), O, S, S (O) and S (O) 2, but two hetero chain members may be present in adjacent positions only if one of them is chosen from the series consisting of S (O) and S (O) 2 and the another is chosen from the series consisting of N (R25), O and S, and the other chain members are the same or different C (R26) (R26) groups; R24 is a monocyclic or bicyclic ring, from 3 members to 10 members, which is saturated and contains 0 or 1 hetero ring members, or is unsaturated and contains 0, 1 or 2 hetero ring members equal or different, where the hetero members of the ring are chosen from the series consisting of N, N (R32), O, S, S (O) and S (O) 2, and where the ring is optionally substituted at the carbon atoms of the ring with one or more same or different substituents chosen from the series consisting of halogen, R33, oxetanyl, HO-, R33-O-, R33-C (O) -O-, R33-S (O) 2-O-, R33-S ( O) m-, H2N-, R33-NH-, R33-N (R33) -, R33-C (O) -NH-, R33-C (O) -N (R71) -, R33-S (O) 2-NH-, R33-S (O) 2-N (R71) -, H2N-S (O) 2-NH-, R33-NH-S (O) 2-NH-, R33-N (R33) - S (O) 2-NH-, H2N-S (O) 2-N (R71) -, R33-NH-S (O) 2-N (R71) -, R33-N (R33) -S (O) 2-N (R71) -, R33-C (O) -, HO-C (O) -, R33-OC (O) -, H2N-C (O) -, R33-NH-C (O) -, R33-N (R33) -C (O) -, H2N-S (O) 2-, R33-NH-S (O) 2-, R33-N (R33) -S (O) 2-, NC-, O2N- and oxo; R26, independently of any other R26 group, is selected from the series consisting of hydrogen, fluorine, C1-4 alkyl and HO-, or two R26 groups attached to the same carbon atom are oxo, or two of the R26 groups or a group R25 and a group R26, together with the chain members included, form a 3 to 7 membered monocyclic ring that is saturated and contains 0, 1 or 2 identical or different hetero ring members selected from the series consisting of N, N (R34), O, S, S (O) and S (O) 2, where the ring is optionally substituted in carbon atoms of the ring by one or more same or different substituents selected from the series consisting of fluorine and alkyl C1-4; R32 and R34 are chosen, independently from each other, from the series consisting of hydrogen, R35, R35-S (O) 2-, R35-C (O) -, R35-O-C (O) - and phenyl; R50 is selected from the series consisting of R51-O- and R52-N (R53) -; R51 is selected from the series consisting of hydrogen and R54; R52 is selected from the series consisting of hydrogen, R55, NC- and R56-S (O) 2-; R53 is selected from the series consisting of hydrogen and R57; R56 is selected from the series consisting of R58 and phenyl; R60, independently of any other R60 group, is selected from the series consisting of hydrogen and C1-4 alkyl; R70 is chosen from the series consisting of HO-, R71-O-, R71-C (O) -O-, R71-S (O) m-, H2N-, R71-NH-, R71-N (R71) -, R71-C (O) -NH-, R71-C (O) -N (R71) -, R71-S (O) 2-NH-, R71-S (O) 2-N (R71) -, HO-C (O) -, R71-OC (O) -, H2N-C (O) -, R71-NH-C (O) -, R71-N (R71) -C (O) -, H2N-S (O) 2-, R71-NH-S (O) 2-, R71-N (R71) -S (O) 2- and oxo; R71, independently of any other R71 group, is selected from C1-4 alkyl, C3-4 cycloalkyl and C3-4 cycloalkyl-C1-2- alkyl; Het1 is a monocyclic 4- to 7-membered heterocyclic ring comprising 1 or 2 identical or different hetero ring members selected from the series consisting of N, N (R60), O, S, S (O) and S (O) 2, where the ring is saturated and is optionally substituted with one or more same or different substituents selected from the series consisting of fluorine and C1-4 alkyl; m, regardless of any other number m, is an integer selected from the series consisting of 0, 1 and 2; phenyl, independently of any other phenyl group, is optionally substituted with one or more same or different substituents selected from the series consisting of halogen, C1-4 alkyl, C1-4 alkyl- and NC-, unless specified otherwise; cycloalkyl, independently of any other cycloalkyl group, and independently of any other substituent in the cycloalkyl, is optionally substituted with one or more same or different substituents selected from fluorine and C1-4 alkyl; alkyl, alkenyl and alkynyl, independently of the alkyl, alkenyl and alkynyl group, and independently of any other substituent in alkyl, alkenyl and alkynyl, is optionally substituted with one or more fluorine substituents; with the proviso that the compound of the formula (1) is not 1 - [(biphenyl-4-carbonyl) -amino] -cyclohexanecarboxylic acid, 1- [4- (2-pyrrolidin-1-yl-ethoxy) - benzoylamino] -cyclohexanecarboxylic acid, 1- [4- (2-piperidin-1-yl-ethoxy) -benzoylamino] -cyclohexanecarboxylic acid, 1- [4- (2-oxo-pyrrolidin-1-yl) -benzoylamino] -cyclohexanecarboxylic acid , 1 - {[4- (2-oxo-pyrrolidin-1-yl) -furan-2-carbonyl] -amino} -cyclohexanecarboxylic acid, 1 - [(2 ', 3-dichloro-biphenyl-4-carbonyl) -amino] -cycloheptanecarboxylic acid methyl ester 1- [4- (4,6-dimethyl-pyrimidin-2-ylsulfanyl) -benzoylamino] -cyclopentanecarboxylic acid ethyl ester 1- [4- (4-oxo-piperidine- 1-iI) -benzoylamino] -cyclopropanecarboxylic acid or 1- [2-chloro-4- (3-hydroxybenzylcarbamoyl) -benzoylamino] -cyclopropanecarboxylic acid. Claim 9: A process for the preparation of a compound of the formula (1) or a pharmaceutically acceptable salt thereof according to any one or more of claims 1 to 8, which comprises reacting a compound of the formula (3) with a compound of the formula (4), wherein the ring A and the groups Y, Z, R20 to R22 and R50 in the compounds of the formulas (3) and (4) are defined as in the compounds of the formula (1 ) and additional functional groups may be present in protected form or in the form of a precursor group, and the group G in the compound of the formula (4) is HO-, C1-4-O- alkyl or halogen. Claim |
| priorityDate | 2009-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 112.